Registration Criteria:

  -  Any patient undergoing bone marrow biopsy with suspicion of or known diagnosis of
     acute myeloid leukemia (AML) will be asked to sign a Prescreening Consent to allow
     for centralized testing of bone marrow/peripheral blood samples.

Randomization Eligibility Criteria:

  -  Patient must have previously untreated FLT3 mutated Non M3 AML (FLT3-TKD or FLT3-ITD
     allowed).

     ° Standard of care induction 7+3 chemotherapy may start prior to randomization using
     same regimen and doses as defined in the protocol while awaiting prescreening test
     results.

  -  Patient must have had no prior systemic therapy for AML, except as noted below:

       -  Hydroxyurea and emergent leukapheresis or preemptive treatment with retinoic
          acid prior to exclusion of Acute Promyelocytic Leukemia (APL) allowed.

       -  Prior therapy for myelodysplastic syndrome (MDS) or myeloproliferative
          neoplasms (MPN) (e.g., thalidomide or lenalidomide, interferon, jakafi,
          cytokines, 5-azacytidine or decitabine, histone deacetylase inhibitors).

       -  Initiation of standard of care 7+3 induction chemotherapy using same regimen
          and doses as defined in protocol while awaiting prescreening test results

  -  Patient may not have received hypomethylating agent within 21 days.

  -  Patient may not have M3 AML.

  -  Patient may not have AML with known Core Binding Factor -t(8;21), inv(16), t(16;16).

  -  Patient may not have known active Central Nervous System (CNS) leukemia.

     ° Prophylaxis with intrathecal chemotherapy is allowed prior to or during
     induction/consolidation.

  -  Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of
     0-3.

  -  Patient must be age ≥ 18 years to ≤ 70 years.

  -  Patient must be able to understand and willing to sign Institutional Review Board
     (IRB)-approved informed consent.

  -  Patient must be willing to provide mandatory bone marrow and blood samples for
     research.

  -  Patient must have adequate organ function as measured by the following criteria,
     obtained ≤ 48 hours prior to randomization except ECG and left ventricular ejection
     fraction (LVEF) which can be done ≤ 2 weeks prior to randomization:

       -  Serum creatinine ≤ 1.5x institutional upper limit of normal (ULN), or if serum
          creatinine outside normal range, then glomerular filtration rate (GFR) >40
          mL/min as measured by Cockcroft-Gault formula.

       -  Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 3x ULN,
          unless secondary to leukemia.

       -  Serum total or direct bilirubin <2 mg/dL, unless due to Gilbert's, hemolysis or
          leukemic infiltration.

       -  Fridericia-Corrected QT Interval (QTcF) interval ≤ 500 msec (using Friderica's
          correction).

       -  Left Ventricular Ejection Fraction >45%.

  -  The patient may not be known to have hypokalemia and/or hypomagnesemia that does not
     respond to supplementation.

  -  A female patient is eligible to participate if she is not pregnant and at least one
     of the following conditions apply:

       -  Not a woman of childbearing potential (WOCBP) OR

       -  WOCBP who agrees to follow the contraceptive guidance throughout the treatment
          period and for at least 180 days after the final study drug administration.

  -  Female patient must agree not to breastfeed or donate ova starting at treatment and
     throughout the study period, and for at least 180 days after the final study drug
     administration.

  -  A male patient must agree not to donate sperm starting at treatment and throughout
     the study period, and for at least 120 days after the final study drug
     administration.

  -  A male patient with female partner(s) of child-bearing potential must agree to use
     contraception during the treatment period, and for at least 120 days after the final
     study drug administration.

  -  Male patient with a pregnant or breastfeeding partner(s) must agree to remain
     abstinent or use a condom for the duration of the pregnancy or time partner is
     breastfeeding throughout the treatment period, and for at least 120 days after the
     final study drug administration.

  -  Patient may not have another malignancy that could interfere with the evaluation of
     safety or efficacy of this combination.

  -  Patient may not have a history of Long QT Syndrome.

  -  Patient may not have evidence of uncontrolled angina, severe uncontrolled
     ventricular arrhythmias, electrocardiographic evidence of acute ischemia, or
     congestive heart failure (CHF) New York Heart Association (NYHA) Class 3 or 4.
     Patient may also not have a history of CHF NYHA Class 3 or 4 in the past, unless a
     prescreening echocardiogram (ECHO) or multigated acquisition scan (MUGA) performed
     within 2 weeks prior to study entry with results of left ventricular ejection
     fraction >45%.

  -  Patient may not have had major surgery or radiation therapy within 4 weeks of
     registration.

  -  Patient may not require treatment with concomitant drugs that are strong inducers of
     CYP3A and P-gp.

  -  Patient with a known allergy to any of the study medications, their analogues, or
     excipients in the various formulations of any agent are not eligible.

  -  Patient with known gastrointestinal (GI) disease or prior GI procedure that could
     interfere with the oral absorption or tolerance of gilteritinib or midostaurin
     including difficulty swallowing are not eligible.

  -  Patient with any serious medical or psychiatric illness that could, in the
     investigator's opinion, potentially interfere with the completion of the treatment
     according to the protocol are not eligible.

  -  Patient may not participate in any other therapeutic clinical trials, including
     those with other investigational agents not included in this trial during treatment
     on this study without prior approval from PrECOG.

Approximately one third of patients with AML have a particular change in their leukemia
cells (called a mutation) in a gene called FLT3. The presence of a FLT3 mutation can be
used to direct treatment options.

This is an open-label phase II study. Patients will receive standard chemotherapy of
daunorubicin and cytarabine during Induction and high-dose cytarabine during
Consolidation. Patients will be randomized to gilteritinib or midostaurin. After
approximately 90 patient's complete treatment, a review of the effectiveness of
gliteritinib compared to midostaurin will be done. If gilteritinib is not as effective as
midostaurin, the study may be stopped.

Bone marrow aspirate and biopsy will be done on Day 21 after start of Induction and after
Induction to assess response. Patients with a complete response may proceed to
consolidation chemotherapy. Another bone marrow aspirate and biopsy will be done after
the first cycle of consolidation is complete.

Mandatory prescreening bone marrow and/or blood samples are required for FLT3 testing.
Any left-over samples will be requested for future research (optional).

Mandatory bone marrow samples for research are required after Induction and if patient
receives Consolidation, after the first cycle of Consolidation.